Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(38%)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
5
38%
Ph phase_2
3
23%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
N/ANon-phased studies
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

13

all time

Status Distribution
Active(5)
Terminated(1)
Other(7)

Detailed Status

unknown7
Recruiting3
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
5
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
N/A5 (55.6%)

Trials by Status

recruiting323%
terminated18%
unknown754%
active_not_recruiting215%

Recent Activity

5 active trials
Showing 5 of 13
recruitingnot_applicable

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
active_not_recruitingphase_2

RANKL Inhibition and Mammographic Breast Density

NCT04067726
recruitingnot_applicable

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

NCT03524430
recruiting

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms

NCT07121998
terminated

Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment

NCT05435352
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06127979Not Applicable

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Recruiting
NCT04067726Phase 2

RANKL Inhibition and Mammographic Breast Density

Active Not Recruiting
NCT03524430Not Applicable

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Recruiting
NCT07121998

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms

Recruiting
NCT05435352

Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment

Terminated
NCT04024878Phase 1

NeoVax With Nivolumab in Patients With Ovarian Cancer

Active Not Recruiting
NCT06120829Not Applicable

Cryobiopsy for Suspected Malignant Peripheral Lymphadenopathy

Unknown
NCT03741517

Biomarker Study of Pancreatic Neuroendocrine Tumours

Unknown
NCT04309136Phase 2

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

Unknown
NCT04612894Phase 2

Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer

Unknown
NCT04568941Not Applicable

Comparison Study of Different Tumor Biopsy Method for Sentinel Lymph Node Biopsy in Breast Cancer

Unknown
NCT03789851Not Applicable

Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer

Unknown
NCT03130205

Biomarker Study in Pancreatic Neuroendocrine Tumours

Unknown

All 13 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
13